#USA #Mahwah #Glenmark Pharmaceuticals #Adderall #Amphetamine Products

Glenmark Pharmaceuticals Launches New Amphetamine Tablets

Glenmark Pharmaceuticals Inc., based in the USA, has recently announced the upcoming release of a new product line that includes Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets. This innovative line will feature various dosage options, including 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. Set for distribution starting May 2025, these tablets are defined as Mixed Salts of a Single Entity Amphetamine Product.

The new tablets are designed to be bioequivalent and therapeutically equivalent to the well-known Adderall® Tablets, which are popular in the U.S. market. Adderall® has established itself as a leading treatment option for Attention Deficit Hyperactivity Disorder (ADHD), amassing significant sales figures in recent years. According to IQVIA™ sales data for the 12 months leading up to February 2025, the Adderall® market generated an impressive $421.7 million, highlighting the demand for effective ADHD medications.

Addressing Market Demand

Marc Kikuchi, President and Business Head for North America at Glenmark, commented on the significance of this launch, stating, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch." This emphasis on fulfilling market needs positions Glenmark as a proactive player in the pharmaceutical landscape, especially in the realm of ADHD treatments.

With ADHD awareness on the rise, many patients and healthcare providers have reported frustrations over the current shortages of Adderall®, making this new product line highly anticipated. Glenmark’s new offerings could potentially lessen the burden on patients who struggle to find their medications amid this scarcity.

Glenmark’s Commitment to Quality

Glenmark Pharmaceuticals Ltd. boasts a robust presence in various therapeutic areas, including cardiac, metabolic, respiratory, dermatological, and oncology segments. The company operates 11 state-of-the-art manufacturing facilities across four continents and has a footprint in more than 80 countries. This diversity and scale allow Glenmark to maintain high standards in production and distribution, ensuring consistent quality for patients worldwide.

The firm has also made notable strides in sustainability. Their Green House Gas (GHG) emission reduction targets recently gained approval from the Science Based Target initiative (SBTi), making them one of the few pharmaceutical companies in India to achieve this accolade. This commitment to environmental responsibility further enhances Glenmark's reputation as an industry leader.

Looking Towards the Future

As Glenmark prepares for the market entry of its Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets, stakeholders in the pharmaceutical sector are keenly observing how this launch will unfold. Not only does it promise to meet an urgent medical need, but it also underscores Glenmark's enduring commitment to innovation and patient care.

In conclusion, the upcoming launch by Glenmark Pharmaceuticals could be a significant turning point in the availability of ADHD treatment options in the U.S. market, potentially providing relief to patients who rely on these medications for better quality of life.

For more information about Glenmark Pharmaceuticals and their product offerings, please visit their official website or follow them on LinkedIn and Instagram.